Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 5,530,000 shares, an increase of 8.0% from the December 31st total of 5,120,000 shares. Currently, 10.0% of the company’s stock are sold short. Based on an average daily volume of 831,700 shares, the short-interest ratio is currently 6.6 days.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now directly owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 4.93% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB raised its holdings in Agios Pharmaceuticals by 8.4% during the fourth quarter. Handelsbanken Fonder AB now owns 19,323 shares of the biopharmaceutical company’s stock worth $635,000 after purchasing an additional 1,500 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in Agios Pharmaceuticals by 13.5% in the fourth quarter. New York State Common Retirement Fund now owns 39,093 shares of the biopharmaceutical company’s stock valued at $1,285,000 after acquiring an additional 4,663 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Agios Pharmaceuticals during the 4th quarter worth approximately $33,000. AlphaCentric Advisors LLC acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter valued at $202,000. Finally, Wingate Wealth Advisors Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter worth about $53,000.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on AGIO shares. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 10th. Scotiabank upped their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Agios Pharmaceuticals has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 2.2 %

AGIO opened at $33.62 on Tuesday. The company has a market cap of $1.92 billion, a PE ratio of 2.96 and a beta of 0.88. The business has a 50 day moving average price of $39.82 and a two-hundred day moving average price of $44.26. Agios Pharmaceuticals has a 52 week low of $22.41 and a 52 week high of $62.58.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.